Treating Older Adults with Generalized Anxiety Disorder

Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

Attendees will learn:
- How anxiety disorders in older adults differ from the disorders in younger adults.
~ They can be more detrimental to health and cognition in older adults.
~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
- Why late-life anxiety disorders are undetected and undertreated.
- The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

Webinar Speaker:
Eric Lenze, MD
Associate Professor, Department of Psychiatry, Washington University School of Medicine

Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
Oct 27 2010
76 mins
Treating Older Adults with Generalized Anxiety Disorder
More from this community:

Medical Research

Webinars and videos

  • Live and recorded (318)
  • Upcoming (6)
  • Date
  • Rating
  • Views
  • This webinar focuses on new methods and applications in food contamination analysis, bringing together some of the leading experts in food contact materials (FCM) and provides an interactive learning environment for scientists working in this field.

    As food quality and food integrity has become a major topic for the consumer, the penetration path of contaminants in our food chain deriving from the food production and/or the food packaging and storage conditions is gaining attention. Fast and reliable ways of sample preparation and analysis are discussed showing up-to-date examples and how the regulations are applied.
    ______________
    ** Meet the speakers **

    - Sabrina Moret (Associate Professor, Dept. Food Science, University of Udine)

    - Duncan Goodwin (Director of Technical Services, NSF)

    - Susanne Feifel (Product Group Manager for Kjeldahl, Elemental Analysis and Extraction, BÜCHI)
    ______________
    ** What will you gain from this webinar? **

    - You will be provided with tangible ways to streamline your sample preparation to detect mineral oil hydrocarbons in cardboard and food as well as bisphenol A in canned food.

    - BUCHI´s solutions for these applications are presented using examples from industry.

    - Furthermore, you will learn about health and safety risks in the field of food packaging and storage. This will be linked to up-to-date information from the leading regulatory authorities.
  • Alongside established drug target classes, innovative approaches are addressing previously undruggable target classes such as protein–protein interactions. This webinar will provide an overview of how compound profiling using the PLA® (Proximity Ligation Assay) technology can be used for in situ analysis of protein interactions by high content screening as part of the Hit-to-Lead workflow, the key advantage being the ability to provide evidence for target engagement of the compound.

    Proximity ligation is a highly specific and sensitive technology to monitor individual proteins, their interactions and post-translational modifications in situ. It provides single molecule resolution and objective and unbiased quantification in cells and tissues on endogenous expression levels.

    Dr. Bernhard Ellinger (Principal Scientist, European ScreeningPort) will describe how the PLA technology has been optimised for use in an automated 384-well screening format with routines for automated image analysis including spot detection, localisation and quantification. He will present a case study of a small molecule drug discovery project performed in collaboration with a biotech partner. The target mechanism involved the disruption of the interaction between amyloid ß oligomers and RAGE (Receptor for Advanced Glycation Endproducts). Profiling of compounds during Hit-to-Lead stages has involved a variety of high content functional cellular assays including PLA. He will discuss the use of PLA in 384-well format as part of a Hit-to-Lead screening cascade to monitor compound-mediated disruption of this receptor-ligand complex.

    Thomas Juehne (Principal Scientist, Sigma-Aldrich) will discuss Duolink®, which is based on the in situ PLA technology, a highly sensitive and selective way of direct in cell visualisation of endogenously expressed proteins and their interacting partners enabling the use of unmodified primary cells.

    The following trademarks are owned by Olink AB: Duolink® and PLA®
  • SLC transporter-mediated drug–drug interactions (DDI) can significantly impact the pharmacokinetics and safety profiles of drugs. The regulatory agencies (FDA/EMA) recent guidance documents recommend testing six SLC transporters for potential DDI: OATP1B1, OATP1B3, OAT1, OAT3, OCT1 and OCT2. The 2013 drug transporter white paper published by the International Transporter Consortium (ITC) identified additional drug transporters relevant to drug development, including the Multidrug and Toxin Extrusion SLC transporters: MATE1 and MATE2-K. The webinar will introduce a novel cell-based SLC transporter model system - the recently launched “Corning™ TransportoCells™” - for studying regulatory agency recommended SLC transporters. The new system provides a convenient “thaw and go”, high performing mammalian cell model which supports regulatory agency recommendations for evaluating transporter mediated drug-drug interactions in vitro. In this webinar, we will provide an overview of the product validation and applications for the TransportoCells™ transporter model system. Validation data will also be presented for the newly available MATE1 and MATE2-K Corning™ TransportoCells™.
  • Despite our dependence on cultured cells as models, issues surrounding cell identity, choice of appropriate cell lines, conditions of their growth and storage, microbial contamination and over-passaging are often overlooked or misunderstood. Mistakes can have devastating impacts on the legitimacy and reproducibility of science but potentially also, on careers, reputations and funding streams.

    Topics covered:

    Solutions and options for managing cell culture processes
    The Impact of misidentification
    The international consensus on cell identity and qualification
  • Attend this webinar to discover:

    •Changes to healthcare delivery: hospitals of the future, aging in place, cost of care innovations
    •Role of the patient and consumer influence
    •Role of emerging regions as a consumer and competitor
    •Novel industry business models
    •Key disruptive technologies
  • The truth about delivering clinical research in the UK

    • Are you looking to deliver your research in Europe?
    • Need multiple, reliable sites in each country?
    • Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last five years the research landscape here has changed dramatically allowing us to make great strides in delivering research for the life-sciences industry. So whether you’re a small CRO, a medium med tech, or a pharma giant - we can help you.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research.. This session will be hosted by Jonathan Sheffield, CEO of the NIHR Clinical Research Network. It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can find out:

    • How much the UK’s market volume of commercial contract research (supported by the NIHR) has changed
    • What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR)
    • On average how many days it takes for NHS sites to get regulatory approval for research to take place (with NIHR support)
    • What percentage of commercial contract studies (supported by the NIHR) are delivered to time and target
    • How the NIHR is keeping clinical research in the public eye
    • How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • The Health Service Journal Clinical Research Impact award winner, Sussex Partnership NHS Foundation Trust, has created an inclusive research network which has given the public, patients, carers and staff the opportunity to learn about and get involved with research in their community.

    Find out why Sussex Partnership were determined to make clinical research everyone’s business and how they implemented their new initiatives.

    This session shares best practice and is aimed at NHS Trusts/primary care practices.
  • Three-dimensional (3D) cell culture environments provide structural and biochemical cues for cellular differentiation and functionality. For specialized cell types such as primary cells, a two-dimensional growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, signal transduction, and tissue-specific gene expression. This webinar will highlight applications that rely on 3D materials and systems, including Corning ® Matrigel® Matrix (reconstituted basement membrane), Collagen Type I, Corning PuraMatrix™ Peptide Hydrogel, and permeable supports (cell culture inserts). To demonstrate the effectiveness of these environments, the biological and functional properties of a variety of cell types will be discussed.
  • Frost & Sullivan will provide an outlook for healthcare in 2014 with detailed insights on the regulatory challenges, investment trends, innovation temperature and emerging business models in the Asia-Pacific Healthcare market.
  • M22 - Neue Behandlungsansätze mit IPL und ResurFX-
    Dr. med. Gerd Kautz.
    PB-1005026Rev A
  • Channel
  • Channel profile
Up Down
  • GAD and Substance Abuse Recorded: Nov 23 2010 70 mins
    Substance use disorders commonly co-occur with anxiety disorders. Diagnosing anxiety disorders in the face of active substance use and withdrawal can be very challenging due to the significant symptom overlap. This symptom overlap often leads to delayed or inadequate treatment. When treating individuals with generalized anxiety disorder and a substance use disorder, benzodiazepines should be avoided. Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors are FDA-approved to treat GAD and are fairly safe in substance users. Other non-FDA approved medications will also be discussed.

    During this webinar, attendees will learn:

    -What symptoms of anxiety overlap with substance use and withdrawal

    - How to diagnose anxiety disorders in the face of substance use

    -Why substance abuse and anxiety disorders co-occur so frequently

    -How to treat individuals with anxiety disorders and comorbid substance abuse

    Dr. Susan Sonne is active in research and teaching as Associate Professor of Psychiatry and Pharmacy at the Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, Clinical Neuroscience Division.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme6
  • GAD and Cormorbidity: Impact on Patient Health Recorded: Nov 9 2010 66 mins
    Generalized Anxiety Disorder (GAD) is common, chronic, and associated with substantial impairment in function and quality of life. GAD commonly occurs comorbid with mood disorders and anxiety disorders. GAD comorbidity has been clearly linked to additive worsening of outcomes and function in both Major Depressive Disorder and in Bipolar Disorder. This presentation will provide an update on current understandings about the incidence and nature of GAD and comorbid disorders, and their impact on patient health.

    During this webinar attendees will:

    1) Understand the overlap of Generalized Anxiety Disorder (GAD) with mood disorders

    2) Understand the impact of GAD comorbidity on severity of illness including suicidality, quality of life and functioning in individuals with GAD

    3) Learn about the need to address GAD and its comorbidities to optimally improve patient health

    Naomi Michele Simon, M.D., M.Sc.

    Dr. Naomi M. Simon is Associate Director of the Center for Anxiety and Traumatic Stress Disorders and Director of the recently established Complicated Grief Program at Massachusetts General Hospital, and is Associate Professor of Psychiatry, Harvard Medical School.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME5
  • Treating Older Adults with Generalized Anxiety Disorder Recorded: Oct 27 2010 76 mins
    By 2050 there will be over 150 million older adults with anxiety disorders globally. Symptoms include sleep disturbance, interference with daily activities and distress, which can lead to medical illness such as coronary heart disease, disability, and higher levels of health care utilization.

    Attendees will learn:
    - How anxiety disorders in older adults differ from the disorders in younger adults.
    ~ They can be more detrimental to health and cognition in older adults.
    ~ These disorders may be more treatment-resistant, requiring aggressive treatment such as the combination of medication and psychotherapy.
    - Why late-life anxiety disorders are undetected and undertreated.
    - The benefits of using antidepressants and Cognitive-Behavioral Therapy as safer alternatives to treatment for these disorders in older adults.

    Webinar Speaker:
    Eric Lenze, MD
    Associate Professor, Department of Psychiatry, Washington University School of Medicine

    Dr. Lenze completed medical school and psychiatry residency at Washington University School of Medicine. He trained in a geriatric psychiatry fellowship and a clinical research fellowship at University of Pittsburgh, then joined the faculty, as part of the Advanced Center for Interventions and Services Research in Late-life mood disorders. In 2007, he returned to Washington University to focus on treatment studies in late-life anxiety disorders and depression. He carries out clinical research in disabled rehabilitating elderly populations and runs a faculty practice treating late-life anxiety disorders and depression.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme4
  • Treating GAD in Primary Care Settings Recorded: Oct 13 2010 78 mins
    Attendees will:
    - recognize symptoms of Generalized Anxiety Disorder in primary care patients
    - use current pharmacological and psychotherapeutic treatments to develop a management plan
    - assess different treatments for comorbid GAD and refractory cases

    Webinar Speaker:
    Larry Culpepper, MD, MPH
    Professor of Family Medicine and Chairman, Department of Family Medicine, Boston University

    Dr. Culpepper has conducted federally funded studies of depression and anxiety, otitis media, and school-based and community interventions to improve pregnancy outcomes and to prevent teen pregnancies. He currently is the principal investigator of an AHRQ funded developmental center for patient safety research devoted to the study of problems affecting low income and minority vulnerable populations in ambulatory care settings, and co-investigator of the Primary Care Anxiety Project, a study of the course of anxiety disorders in primary care settings.

    Dr. Culpepper also is Chief of Family Practice at Boston Medical Center. He received his MD degree from Baylor College of Medicine and his MPH degree from Boston University.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/adaa_cme3
  • Psychosocial Treatments for Generalized Anxiety Disorder Recorded: Oct 8 2010 72 mins
    Attendees will:
    - Discuss current evidence-based psychotherapeutic treatments for adults with generalized anxiety disorder.
    - Identify characteristics of generalized anxiety disorder.
    - Design a psychosocial treatment plan with patients with GAD.

    Webinar Speaker:
    Douglas Mennin, PhD
    Associate Professor of Psychology, Yale University and Director of the Yale Anxiety and Mood Services Clinic

    Dr. Mennin has focused his research program on understanding and treating chronic and reoccurring bouts of anxiety and mood disorders, particularly worry, stress, and depression. Our understanding of problems related to anxiety and depression has increased exponentially in the past twenty years. Advances in biological and behavioral technologies has helped us shine light on how everyday feelings such as fear and sadness can, in some individuals, translate into emotional disorder.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME2
  • Understanding & Treating Generalized Anxiety Disorder Recorded: Sep 21 2010 77 mins
    Attendees will:
    - discuss the neurobiology of GAD
    - recognize symptoms and diagnose individuals with generalized anxiety disorder
    - plan evidence-based treatment for individuals with GAD and gad and comorbid disorders including depression, sleep disorders, cardiac illnesses and IBS.

    Webinar speaker:
    Mark Pollack, MD, Director, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital
    Professor of Psychiatry, Harvard Medical School

    Dr. Pollack’s areas of clinical and research interest include the acute and long-term course, pathophysiology, and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.

    Blackwell Futura Media Services designates this educational activity for 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Blackwell Futura Media Services is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. DETAILS at: http://bit.ly/ADAA_CME1
Anxiety disorders are real, serious & treatable
Anxiety disorders are real, serious & treatable

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Treating Older Adults with Generalized Anxiety Disorder
  • Live at: Oct 27 2010 5:00 pm
  • Presented by: Eric Lenze, MD Associate Professor, Department of Psychiatry, Washington University School of Medicine
  • From:
Your email has been sent.
or close
You must be logged in to email this